Poseida Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q2 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Poseida Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2019 to Q3 2024.
  • Poseida Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $19.7M.
  • Poseida Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$62.5M, a 54.3% increase year-over-year.
  • Poseida Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$130M, a 116% decline from 2022.
  • Poseida Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$59.9M, a 57.6% increase from 2021.
  • Poseida Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$141M, a 11.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$62.5M $19.7M +$56M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$118M -$31.8M -$3.9M -14% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 -$115M -$24.6M +$14.9M +37.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$130M -$25.9M +$7.31M +22% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$137M -$36.2M -$108M -150% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$28.8M -$27.9M +$13.7M +33% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$42.5M -$39.5M +$17.4M +30.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$59.9M -$33.2M -$15.7M -90.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$44.2M $71.8M +$113M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$158M -$41.5M +$3.33M +7.43% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$161M -$57M -$19.5M -52% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$141M -$17.5M +$17.9M +50.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$159M -$41.6M -$8.12M -24.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$151M -$44.9M -$15.4M -52.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$136M -$37.5M -$9.2M -32.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$127M -$35.4M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$33.5M -$12.7M -61.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$29.4M -$1.1M -3.89% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$28.3M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q3 2019 -$20.8M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$28.3M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.